Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04163263 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of Repeat Topical Application of BOS-356 in Subjects With Moderate to Severe Acne Vulgaris
A Phase 1 study, sponsored by Boston Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT04163263 is a Phase 1 study that has completed, run by Boston Pharmaceuticals. The registered enrollment target is 66 participants.
The verdict
NCT04163263, a Phase 1 study, has completed, sponsored by Boston Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
This study is being conducted to characterize the safety and tolerability of BOS-356 in adult participants with moderate to severe acne vulgaris following 14 days or 28 days of repeated topical application
Interventions
- DRUG Vehicle
- DRUG BOS-356
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2019-11-04 |
| Est. Completion | 2020-11-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04163263
The ClinicalTrials.gov registry entry for NCT04163263 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT04163263 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04163263 about?
NCT04163263 is a clinical study titled "Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of Repeat Topical Application of BOS-356 in Subjects With Moderate to Severe Acne Vulgaris". This study is being conducted to characterize the safety and tolerability of BOS-356 in adult participants with moderate to severe acne vulgaris following 14 days or 28 days of repeated topical application
What is the current status of trial NCT04163263?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2019-11-04. Estimated completion is 2020-11-11.
What interventions are being tested in trial NCT04163263?
The interventions under investigation include: Vehicle (DRUG), BOS-356 (DRUG).
Who is sponsoring clinical trial NCT04163263?
This trial is sponsored by Boston Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.